Scienture Holdings, Inc.
SCNX Healthcare Pharmaceutical Retailers
Scienture Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $431,600.00, up 216.0% from fiscal 2024. In the quarter to June 2026, revenue grew 3,235.9%, EPS grew 85.4%, free cash flow fell 54.0% and total debt rose 831.4%, each against the same quarter a year earlier.
Follow SCNX
Scienture Holdings, Inc. (SCNX) EV/Sales
As of 16 October 2026, Scienture Holdings, Inc. (SCNX) trades at a EV/Sales of 162×. Over the past ten years it has ranged from 5.5× (December 2022) to 5,762× (August 2025); the current reading is higher than 57% of that period. That is above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 394× | (80.84%) |
| FY2024 | 2,058× | 2,640.25% |
| FY2023 | 75.1× | 1,139.66% |
| FY2022 | 6.1× | (87.48%) |
| FY2021 | 48.4× | (18.34%) |
| FY2020 | 59.2× | (54.88%) |
| FY2019 | 131× | 108.08% |
| FY2018 | 63.1× | (48.63%) |
| FY2017 | 123× | (16.03%) |
| FY2016 | 146× | (50.56%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 424× | (28.16%) |
| Mar 2026 | 591× | 49.84% |
| Dec 2025 | 394× | (30.00%) |
| Sep 2025 | 563× | (75.57%) |
| 40 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MDVLQ MedAvail Holdings, Inc. compare | −0.3× |
| BIMI BIMI Holdings Inc. compare | −0.1× |
| RDGT Ridgetech Inc. compare | 0.0× |
| POM Pomdoctor Limited - Sponsored ADR compare | n/m |
| PETS PetMed Express, Inc. compare | 0.1× |
| HITI High Tide Inc. compare | 0.5× |
| MEDS DataMeds AI, Inc compare | 3.0× |
| SCNX Scienture Holdings, Inc. | 162× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)